SoftOx Solutions AS (OSL:SOFTX)
0.0862
-0.0038 (-4.22%)
At close: May 27, 2025
SoftOx Solutions AS Company Description
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway.
The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections.
It is also developing antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norway.
SoftOx Solutions AS
Country | Norway |
Founded | 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Thomas Bjarnsholt |
Contact Details
Address: Martin Linges vei 25 Fornebu, 1364 Norway | |
Phone | 47 91 87 61 65 |
Website | soft-ox.com |
Stock Details
Ticker Symbol | SOFTX |
Exchange | Oslo Børs |
Fiscal Year | January - December |
Reporting Currency | NOK |
ISIN Number | NO0010811961 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Thomas Bjarnsholt | Chief Executive Officer, Chief Medical Officer and Chief Scientific Officer |
Ingrid Juven | Chief Operating Officer and Chief Financial Officer |
Elin Lisby Kastberg Jørgensen | International Senior Project Manager |